Ginkgo Bioworks Holdings, Inc.

Equities

DNA

US37611X1000

Biotechnology & Medical Research

Market Closed - Nyse 04:00:02 2024-03-27 pm EDT After market 07:12:58 pm
1.1 USD +2.80% Intraday chart for Ginkgo Bioworks Holdings, Inc. 1.1 0.00%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Ginkgo Bioworks, AQUA Cultured Foods to Support Fish-Free Seafood Production MT
AQUA Cultured Foods Partners with Ginkgo Bioworks to Optimize Alt-Seafood Production CI
Ginkgo Bioworks, Imagindairy to Develop Animal-Free Dairy Proteins MT
Imagindairy and Ginkgo Bioworks Collaborate to Develop and Produce Animal-Free Non-Whey Dairy Proteins CI
Ginkgo Bioworks Collaborating With Dutch Biotech ProteoNic to Extend Proteins Production, Genetic Therapies MT
Transcript : Ginkgo Bioworks Holdings, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 02:10 PM
TD Cowen Cuts Price Target on Ginkgo Bioworks to $3 From $7, Maintains Outperform Rating MT
Transcript : Ginkgo Bioworks Holdings, Inc., Q4 2023 Earnings Call, Feb 29, 2024
Ginkgo Bioworks Q4 Loss Widens, Revenue Declines; 2024 Revenue Guidance Set; Shares Slump After Hours MT
Ginkgo Bioworks Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Ginkgo Bioworks Holdings, Inc. Provides Revenue Guidance for the Year 2024 CI
Ginkgo Bioworks Holdings, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Earnings Flash (DNA) GINKGO BIOWORKS Posts Q4 Revenue $35M MT
Ginkgo Bioworks Acquires Reverie Labs, Proof Diagnostics, Patch Biosciences MT
Ginkgo Bioworks Holdings, Inc. acquired Proof Diagnostics, Inc. from Arch Venture Partners, L.P., Madrona Venture Group, LLC and Impresa Management LLC. CI
Ginkgo Bioworks, Agenus Unit Win Contract to Discover, Develop Vaccine Adjuvants MT
Ginkgo Bioworks and Saponiqx Wins MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular Design CI
Ginkgo's New Integrated Data Generation Facility Set to Launch in 2025 CI
Goldman Sachs Trims Ginkgo Bioworks Price Target to $1.10 From $1.25, Maintains Sell Rating MT
Transcript : Ginkgo Bioworks Holdings, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 09:45 AM
Ginkgo Bioworks Holdings Reaffirms 2023 Revenue Guidance MT
Ginkgo Bioworks Holdings, Inc. Provides Revenue Guidance for the Year 2023 CI
Ginkgo Bioworks Announces Inaugural Members of New Biopharma Advisory Board CI
Ginkgo Bioworks Holdings Insider Sold Shares Worth $309,900, According to a Recent SEC Filing MT
Ginkgo Bioworks Completes Program with Biogen to Boost Productivity of Gene Therapy Manufacturing Platform CI
Chart Ginkgo Bioworks Holdings, Inc.
More charts
Ginkgo Bioworks Holdings, Inc. provides horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its cell programs are designed to enable biological production of products as diverse as therapeutics, key food ingredients and chemicals derived from petroleum. Its Foundry segment consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two assets: the Foundry, biology lab facilities, enabled by investment in workflows, custom software, robotic automation, and data science and analytics. Its Biosecurity segment consists of COVID-19 testing products and services primarily provided to public health authorities. It also owns the adeno-associated virus capsid discovery and engineering platform assets.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
1.1 USD
Average target price
1.97 USD
Spread / Average Target
+79.09%
Consensus
  1. Stock
  2. Equities
  3. Stock Ginkgo Bioworks Holdings, Inc. - Nyse
  4. News Ginkgo Bioworks Holdings, Inc.
  5. Sector Update: Health Care Stocks Cross Friday Finish Line Slightly Higher